Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment

2005 ◽  
Vol 26 (5) ◽  
pp. 585-586 ◽  
Author(s):  
M. Flint Beal
2010 ◽  
Vol 6 ◽  
pp. S503-S504 ◽  
Author(s):  
Inês Baldeiras ◽  
Isabel Santana ◽  
Maria Teresa Proença ◽  
Maria Helena Garrucho ◽  
Rui Pascoal ◽  
...  

Author(s):  
Eesha Kokje ◽  
Simge Celik ◽  
Hans-Werner Wahl ◽  
Christiane von Stutterheim

AbstractA number of linguistic and cognitive deficits have been reported during the course of Alzheimer’s disease (AD) and its preceding stage of mild cognitive impairment (MCI), with some deficits appearing years before onset of clinical symptoms. It continues to be a critical task to identify tools that may serve as an early marker of pathology that are also reliably able to distinguish AD from normal ageing. Given the limited success of classic psychometric cognitive testing, a novel approach in assessment is warranted. A potentially sensitive assessment paradigm is discourse processing. The aim of this review was to synthesize original research studies investigating comprehension of discourse in AD and MCI, and to evaluate the potential of this paradigm as a promising avenue for further research. A literature search targeting studies with AD or MCI groups over 60 years of age was conducted in PubMed, Web of Science, and PsycINFO databases. Eight articles with good quality were included in the review. Six measures of discourse comprehension—naming latency, summary, lesson, main idea, proportion of inferential clauses, true/false questions—were identified. All eight studies reported significant deficits in discourse comprehension in AD and MCI groups on five of the six measures, when compared to cognitively healthy older adults. Mixed results were observed for associations with commonly used cognitive measures. Given the consistent findings for discourse comprehension measures across all studies, we strongly recommend further research on its early predictive potential, and discuss different avenues for research.


2010 ◽  
Vol 21 (4) ◽  
pp. 1165-1177 ◽  
Author(s):  
Inês Baldeiras ◽  
Isabel Santana ◽  
Maria Teresa Proença ◽  
Maria Helena Garrucho ◽  
Rui Pascoal ◽  
...  

2021 ◽  
Vol 74 (1) ◽  
pp. 68-71
Author(s):  
Olga E. Dubenko ◽  
Olha S. Chyniak ◽  
Olexander O. Potapov

The aim: To research differences of interleukin (IL)-17 and IL-23 serum levels in patients with Alzheimer’s disease, vascular dementia and mild cognitive impairment. Material and methods: Serum levels of IL-17 and IL-23 were measure by ELISA for 15 patients with Alzheimer’s disease, 14 with vascular dementia, 30 with mild cognitive impairment and 30 control individuals without cognitive impairment. Results: Serum concentrations of IL-17 were significantly higher in Alzheimer’s disease patients (P=0.0023) than control, in vascular dementia no significant differences(P=0.4154). Level of IL-23 was significantly higher than control in Alzheimer’s disease patients (P=0.0170) and vascular dementia (P=0.0002), but in Alzheimer’s disease it was in 12.5 time higher. In total mild cognitive impairment patients no significant differences in interleukin concentration with control, but significant differences observed for amnestic form in IL-17 (P=0.0436) and IL-23 (P=0.0019). Conclusions: IL-17 and IL-23 level significant higher in Alzheimer’s disease patients compared with control and vascular dementia. From mild cognitive impairment levels of detectable interleukins was higher in amnestic form that may be early marker of progression in Alzheimer’s disease.


2008 ◽  
Vol 15 (1) ◽  
pp. 117-128 ◽  
Author(s):  
Inês Baldeiras ◽  
Isabel Santana ◽  
Maria Teresa Proença ◽  
Maria Helena Garrucho ◽  
Rui Pascoal ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document